Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 211Neoplasm Metastasis 16Neoplasms 9Breast Neoplasms, Male 7Breast Diseases 7Ovarian Neoplasms 4Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Intraductal, Noninfiltrating 3Breast Carcinoma In Situ 3Breast Cancer Metastatic 3Advanced Breast Cancer 3Recurrence 2Prostatic Neoplasms 2Neoplasms by Site 2Carcinoma, Renal Cell 2Bulbo-Spinal Atrophy, X-Linked 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Tuberous Sclerosis 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sleep Wake Disorders 1Skin Diseases 1Sexuality 1Sexual Dysfunctions, Psychological 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Primary Breast Cancer ER+ve 1

Interventions

Cyclophosphamide 151Dexamethasone 140Rituximab 83fludarabine 78Cytarabine 69Lenalidomide 68Bortezomib 63fludarabine phosphate 62Gemcitabine 62venetoclax 54Etoposide 53pembrolizumab 52pomalidomide 48Paclitaxel 48Cisplatin 47Carboplatin 47Peripheral Blood Stem Cell Transplantation 46Filgrastim 40Radiotherapy 39Calcium Dobesilate 36Busulfan 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 29Vincristine 28Temozolomide 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Recurrence × exemestane × Clear all
NCT07062965 2026-05-06

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Pfizer

Phase 3 Recruiting
400 enrolled
Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT06105632 2026-02-13

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Pfizer

Phase 2 Active not recruiting
333 enrolled
Breast

Breast Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡